Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Mr. Ricky  Hopson

President, Division Head for BioProduct Delivery & Chief of Staff

Mr. Joseph A. Ferraro J.D.

Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary

Mr. Michael J. Grippo

Senior Vice President of Strategy & Corporate Development

Mr. Michael J. Hatzfeld Jr.

Vice President & Chief Accounting Officer

Dr. Aristippos  Gennadios Ph.D.

Group President of Pharma & Consumer Health Segment

Mr. John J. Greisch M.B.A.

Executive Chairman of the Board

Mr. Alessandro  Maselli

President, Chief Executive Officer & Director

Mr. Matti M. Masanovich

Senior Vice President & Chief Financial Officer

Mr. Charles  Lickfold

Senior Vice President & Chief Information Officer

Mr. Paul  Surdez

Vice President of Investor Relations

Pavadinimas	Rinkos kapitalizacija
China Medical System Holdings Limited	0M
TILT Holdings Inc.	0M
ZhuZhou QianJin Pharmaceutical Co.,Ltd	0M
Wockhardt Limited	0M
Chong Kun Dang Pharmaceutical Corp.	0.1M
Eris Lifesciences Limited	0M
Shenzhen Kangtai Biological Products Co., Ltd.	0M
Takeda Pharmaceutical Company Limited	0M
Medical Developments International Limited	0M
Alembic Pharmaceuticals Limited	0M
Hanmi Pharm. Co., Ltd.	0.3M

Catalent, Inc.

Catalent, Inc. Konkurentų sąrašas

Pagrindiniai konkurentai